title: Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease.
abstract: Administration of anti-tumor necrosis factor antibody (anti-TNF, infliximab) down-regulates T helper 1 (Th 1) cytokines production in intestinal mucosa of patients with Crohn's disease (CD). Interleukin 10 (IL-10) is thought to be involved in CD pathogenesis through regulation of the Th 1 response. The aim of this study was to determine the IL-10 response in CD patients treated with anti-TNF. Fourteen patients with active CD received 5 mg/kg of infliximab; clinical activity assessed by Crohn's Disease Activity Index (CDAI), alpha1-acid glycoprotein and serum IL-10 were determined before and after treatment, in month 0, 1 and 5. In the group with a good clinical response, IL-10 levels diminished significantly in month 1 (p<0.05) and remained decreased in month 5. The group with a lower response showed a significant increase in IL-10 levels in month 1 (p<0.05). alpha1-acid glycoprotein levels obtained before treatment were significantly elevated in the group with a good clinical response (p<0.05) and a significant decrease in month 1 was observed in this group (p<0.05). These observations suggest that a pattern of IL-10 response might be related to the clinical response to anti-TNF treatment in CD.
authors.affiliation: Department of Internal Medicine, Dérer's Hospital, Medical Faculty, Comenius University, Bratislava, Slovak Republic. zdetkova@yahoo.co.uk
authors.forename: Z
authors.initials: Z
authors.lastname: Detková
authors.forename: V
authors.initials: V
authors.lastname: Kupcová
authors.forename: M
authors.initials: M
authors.lastname: Príkazská
authors.forename: L
authors.initials: L
authors.lastname: Turecký
authors.forename: S
authors.initials: S
authors.lastname: Weissová
authors.forename: E
authors.initials: E
authors.lastname: Jahnová
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D009961:Orosomucoid / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D009961:Orosomucoid; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D000069285:Infliximab